Advertisement

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Advertisement

Advertisement




Jun
15
Today In Oncology
Molecular Assay Identifies Patients With Early NSCLC Likely to Benefit From Adjuvant Chemotherapy
HER3-Targeted Antibody-Drug Conjugate for Treatment-Resistant Solid Tumors
Neoadjuvant Nivolumab and Chemotherapy Shows Significant OS Benefit at 5 Years in Resectable NSCLC
SWOG S2302 Pragmatica-Lung Study Design Still Significant Even With Negative Results in Advanced NSCLC
Diagnostic Accuracy of Navigational Bronchoscopy vs Transthoracic Needle Biopsy in Lung Nodules
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo